A phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type reovirus (REOLYSIN) in combination with radiation in patients with advanced malignancies

Trial Profile

A phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type reovirus (REOLYSIN) in combination with radiation in patients with advanced malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2010

At a glance

  • Drugs Pelareorep (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 May 2010 Final results have been reported in Clinical Cancer Research according to an Oncolytics Biotech media release.
    • 11 Mar 2008 Status changed from in progress to completed as reported on the Oncolytics Biotech website.
    • 21 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top